PALO ALTO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK) announced that the U.S. Food and Drug Administration (FDA)
has removed the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286)
clinical trials. This action follows a complete review of TELCYTA data by
the agency and permits the resumption of TELCYTA clinical development.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat serious diseases. The company's most advanced drug development
candidates are TELCYTA, a tumor-activated small molecule product candidate
in clinical development for the treatment of advanced ovarian cancer and
non- small cell lung cancer; and TELINTRA(R), which is in clinical
development for the treatment of myelodysplastic syndrome. Telik's product
candidates were discovered using its proprietary drug discovery technology,
TRAP(R), which enables the rapid and efficient discovery of small molecule
This press release contains "forward-looking" statements, including
statements regarding plans for future clinical development of TELCYTA.
Words such as "will," "plans" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are
based upon Telik's current expectations. There are important factors that
could cause Telik's results to differ materially from those indicated by
these forward- looking statements, including, among others, that if
clinical trials of TELCYTA are further delayed or unsuccessful, Telik's
business would suffer, and if Telik does not obtain regulatory approval to
market products in the United States and foreign countries, Telik will not
be permitted to commercialize its product candidates. Detailed information
regarding factors that may cause actual results to differ materially from
the results expressed or implied by statements in this press release may be
found in Telik's periodic filings with the Securities and Exchange
Commission, including the factors described in the section entitled "Risk
Factors" in its quarterly report on Form 10-Q for the quarter ended June
30, 2007. Telik does not undertake any obligation to update forward-looking
statements contained in this press release.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or
registered trademarks of Telik, Inc.
SOURCE Telik, Inc.